Single-dose cefotaxime intramuscularly cures gonococcal ophthalmia neonatorum

PHILIPPE LEPAGE, JOS BOGAERTS, PHILIPPE KESTELYN, AND ANDRÉ MEHEUS

From the 1Departments of Paediatrics, Microbiology, and Ophthalmology, Kigali Hospital, BP 879, Kigali, Rwanda, and the 2World Health Organisation, Programme Manager, Sexually Transmitted Diseases, Geneva

SUMMARY Nine neonates with culture proved gonococcal ophthalmia neonatorum were treated with a single intramuscular injection of 100 mg/kg of cefotaxime without topical antibiotic therapy. Five of the nine strains were penicillinase-producing Neisseria gonorrhoeae. All nine cases were clinically and microbiologically cured, and no side effects were observed.

Gonococcal ophthalmia neonatorum ceased to be a public health problem once silver nitrate ocular prophylaxis was systematically introduced early this century. In industrialised countries the condition lost its blinding character in the 1940s when penicillin became generally available.

With the emergence and spread of penicillinase-producing Neisseria gonorrhoeae (PPNG) strains since 1976 other antibiotics such as the third generation cephalosporins and kanamycin were introduced for the treatment of these infections. The prevalence of PPNG strains remains low in industrialised countries, but in the developing world, in particular in South-east Asia and Africa, they account for up to 20 to 80% of circulating gonococcal strains. Hence gonococcal ophthalmia neonatorum may again become a blinding disease in these parts of the world unless effective and simple treatment schedules are available.

This study reports the results of treating gonococcal ophthalmia neonatorum with a single dose of cefotaxime 100 mg/kg intramuscularly.

Material and methods

Cases of gonococcal ophthalmia neonatorum seen at the paediatric outpatient department of Kigali Hospital, Rwanda, Central Africa, during the year 1985 are included in this study.

In neonates with purulent conjunctivitis a presumptive clinical diagnosis was confirmed by Gram stain and culture for N. gonorrhoeae on modified Thayer-Martin medium. All nine cases included had a positive culture, and all strains were tested for β-lactamase production by the chromogenic cephalosporin test. Three cases were referred from peripheral health units and had received antibiotic therapy.

The patients were treated with a single intramuscular injection of cefotaxime 100 mg/kg, without topical antibiotics. Mothers received a single dose of spectinomycin 2 g intramuscularly as epidemiological treatment.

The infants were examined by an ophthalmologist (KP) before and after treatment to monitor eventual corneal complications. A follow-up examination was planned for 3 and 7 days after the day of treatment, and conjunctival swabs were taken for control cultures.

Results

Characteristics of the nine patients and results of antimicrobial therapy are summarised in Table 1. Their ages ranged from 2 to 36 days with a median age of 9 days. Four infants were male and five female. All the patients presented with a purulent ocular discharge, which was bilateral in seven of the nine. One presented with gonococcal ophthalmia neonatorum and a purulent otitis media; cefotaxime treatment was continued for five days in this case.

Five out of the nine isolates proved to be PPNG strains. All nine patients were clinically cured without any residual eye damage. Moreover, all follow-up cultures were negative for N. gonorrhoeae.
Single-dose cefotaxime intramuscularly cures gonococcal ophthalmia neonatorum

Table 1  Gonococcal ophthalmia neonatorum treated with cefotaxime 100 mg/kg single dose intramuscularly: characteristics of patients and treatment results

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (days)</th>
<th>Sex</th>
<th>Weight (kg)</th>
<th>Clinical features</th>
<th>Previous therapy</th>
<th>β-lactamase</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical</td>
</tr>
<tr>
<td>1</td>
<td>13</td>
<td>F</td>
<td>3-4</td>
<td>Bilat.</td>
<td>-</td>
<td>-</td>
<td>Cured (day 3)</td>
</tr>
<tr>
<td>2</td>
<td>13</td>
<td>F</td>
<td>2-3</td>
<td>Bilat.</td>
<td>Penicillin IM for 6 days</td>
<td>+</td>
<td>Cured (day 2 and 7)</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>F</td>
<td>1-6</td>
<td>Bilat.</td>
<td>-</td>
<td>+</td>
<td>Cured (day 2, 5 and 7)</td>
</tr>
<tr>
<td>4</td>
<td>7</td>
<td>M</td>
<td>2-0</td>
<td>Bilat.*</td>
<td>Penicillin IM for 4 days + chloromycetin eye ointment</td>
<td>+</td>
<td>Cured (day 4 and 6)</td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>F</td>
<td>3-3</td>
<td>Unilat.</td>
<td>-</td>
<td>+</td>
<td>Cured (day 4, 7, and 11)</td>
</tr>
<tr>
<td>6</td>
<td>17</td>
<td>M</td>
<td>2-8</td>
<td>Bilat.</td>
<td>Tetracycline eye ointment</td>
<td>-</td>
<td>Cured (day 3)</td>
</tr>
<tr>
<td>7</td>
<td>36</td>
<td>M</td>
<td>3-4</td>
<td>Bilat.</td>
<td>-</td>
<td>-</td>
<td>Cured (day 4)</td>
</tr>
<tr>
<td>8</td>
<td>9</td>
<td>M</td>
<td>2-9</td>
<td>Bilat.</td>
<td>-</td>
<td>+</td>
<td>Cured (day 3 and 8)</td>
</tr>
<tr>
<td>9</td>
<td>11</td>
<td>F</td>
<td>3-15</td>
<td>Unilat.</td>
<td>-</td>
<td>-</td>
<td>Cured (day 5)</td>
</tr>
</tbody>
</table>

*Plus right purulent otitis media (culture negative on day 0); received cefotaxime 100 mg/kg/day intramuscularly in two doses for five days.

Discussion

These data show that cefotaxime in a single intramuscular injection of 100 mg/kg without topical antibiotic therapy effectively cures gonococcal ophthalmia neonatorum due to PPNG and non-PPNG strains.

It has been demonstrated that gonococcal ophthalmia neonatorum should be treated by systemic antibiotics either alone or in combination with local treatment, but not by local therapy alone. Until recently penicillin was the treatment of choice worldwide, and a schedule of aqueous benzylpenicillin, 50,000 units/kg/day given intravenously in two doses for seven days with admission of the neonate to hospital was recommended.

Following the emergence of PPNG strains cases of gonococcal ophthalmia neonatorum due to these strains have been reported. So long as the prevalence of PPNG infections remains low, and provided very close supervision of the newborn babies' eyes is possible, it is still acceptable to initiate therapy with penicillin. These conditions are not met within developing countries: strict medical supervision is often impossible, and the prevalence of PPNG strains among circulating gonococci is above 20% in most countries. In Rwanda 52% of gonococcal isolates are PPNG strains, and of the non-PPNG strains 26% are chromosomally resistant to penicillin.

Penicillin treatment is inappropriate in such circumstances, and if one wants to prevent blindness as a complication of gonococcal ophthalmia neonatorum highly effective antibiotic treatment has to be instituted from the start.

Treatment by a single dose presents a great advantage over multidose schedules, as does a regimen without eye ointment or drops. Local therapy to the eyes of the newborn is difficult in poor conditions, has low compliance, and may itself cause infections.

Single-dose intramuscular kanamycin if combined with a topical antibiotic for three days has been shown to be effective in gonococcal ophthalmia neonatorum due to PPNG and non-PPNG strains. But although otoxicity is unlikely with single-dose kanamycin therapy the potential for it makes it difficult to recommend the regimen as a first choice. Cefotaxime or gentamicin has been recommended for gonococcal ophthalmia neonatorum due to PPNG. A case report showed that cefotaxime 100 mg/kg/day for seven days was effective. As the third generation cephalosporins were shown to be highly effective in single-dose treatment of gonococcal infections in adults, their effectiveness in gonococcal ophthalmia neonatorum could be expected. A single intramuscular dose of 125 mg of ceftriaxone was reported to have been effective in seven cases, and the present study shows excellent results with a single-dose of cefotaxime.

A working group of the World Health Organisation recommended the addition of tetracycline ointment 1% for 10 days to a single intramuscular injection of 100 mg/kg of cefotaxime. Our study proves that additional topical antibiotic therapy is not required. Lower doses of cefotaxime, for instance a single intramuscular injection of 50 mg/kg, are probably as effective and should be studied further.

References

8 Sexually transmitted diseases. Treatment guidelines, 1982. MMWR 1982; 31 (suppl): 33S–60S.

Accepted for publication 4 March 1988.
Single-dose cefotaxime intramuscularly cures gonococcal ophthalmia neonatorum.

P Lepage, J Bogaerts, P Kestelyn and A Meheus

doi: 10.1136/bjo.72.7.518

Updated information and services can be found at:

http://bjo.bmj.com/content/72/7/518

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/